Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Molecular targets of FTY720 (fingolimod).
Animal Models in Neurology: Drawbacks and Opportunities.
The influence of HLA-DRB1*15 on motor cortical pathology in multiple sclerosis.
Leber's hereditary optic neuropathy associated with multiple sclerosis: Harding's syndrome.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Potential T cell epitopes of Mycobacterium tuberculosis that can instigate molecular mimicry against host: implications in autoimmune pathogenesis.
Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?
Severe haematological complications during treatment with natalizumab.
Decreased Frontal Lobe Gray Matter Perfusion in Cognitively Impaired Patients with Secondary-Progressive Multiple Sclerosis Detected by the Bookend Technique.
Rectus abdominis muscle endometriotic mass in a woman affected by multiple sclerosis.
A telerehabilitation program by virtual reality-video games improves balance and postural control in multiple sclerosis patients.
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Blockade of the High-Affinity Interleukin-2 Receptors with Daclizumab High-Yield Process: Pharmacokinetic/Pharmacodynamic Analysis of Single- and Multiple-Dose Phase I Trials.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Detecting cortical lesions in multiple sclerosis at 7 T using white matter signal attenuation.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Safety Study of GNbAC1 in Multiple Sclerosis Patients
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis
[Optical coherence tomography in multiple sclerosis].
UW-SES: A new self-efficacy scale for people with disabilities.
Laquinimod in multiple sclerosis.
Benign Multiple Sclerosis: Does it exist?
Death receptor 6 negatively regulates oligodendrocyte survival, maturation and myelination.

Pages